Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalTimes Interest Earned

Altimmune (ALT) Return on Sales: 2011-2024

Historic Return on Sales for Altimmune (ALT) over the last 12 years, with Jun 2024 value amounting to -247.79%.

  • Altimmune's Return on Sales was N/A to -247.79% in Q2 2024 from the same period last year, while for Jun 2024 it was -247.79%, marking a year-over-year change of. This contributed to the annual value of -207.62% for FY2023, which is N/A change from last year.
  • Per Altimmune's latest filing, its Return on Sales stood at -247.79% for Q2 2024, which was down 9.38% from -226.54% recorded in Q1 2024.
  • Altimmune's 5-year Return on Sales high stood at -4.03% for Q4 2020, and its period low was -247.79% during Q2 2024.
  • Its 3-year average for Return on Sales is -136.29%, with a median of -189.39% in 2023.
  • In the last 5 years, Altimmune's Return on Sales skyrocketed by 116bps in 2020 and then plummeted by 16,316bps in 2023.
  • Altimmune's Return on Sales (Quarterly) stood at -4.03% in 2020, then tumbled by 1,798bps to -22.02% in 2021, then tumbled by 191bps to -26.24% in 2022, then plummeted by 16,316bps to -207.93% in 2023, then reached -247.79% in 2024.
  • Its last three reported values are -247.79% in Q2 2024, -226.54% for Q1 2024, and -207.93% during Q4 2023.